Reduced Intensity Conditioning for Allogeneic Hematopoietic Stem-Cell Transplant Determines the Kinetics of Acute Graft-Versus-Host Disease

被引:24
|
作者
Turner, Brie E. [1 ]
Kambouris, Melinda E. [1 ]
Sinfield, Laura [1 ]
Lange, Janusz [1 ]
Burns, Ann M. [1 ]
Lourie, Rohan [2 ]
Atkinson, Kerry [1 ]
Hart, Derek N. J. [3 ]
Munster, David J. [3 ]
Rice, Alison M. [1 ]
机构
[1] Mater Med Res Inst, Biotherapy Program, Brisbane, Qld 4101, Australia
[2] Mater Hlth Serv, Brisbane, Qld 4101, Australia
[3] Mater Med Res Inst, Dendrit Cell Program, Brisbane, Qld 4101, Australia
关键词
Graft-versus-host disease; Reduced intensity conditioning; Dendritic cells;
D O I
10.1097/TP.0b013e3181874787
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Preparative myeloablative conditioning regimens for allogeneic hematopoietic stem-cell transplantation (HSCT) may control malignancy and facilitate engraftment but also contribute to transplant related mortality, cytokine release, and acute graft-versus-host disease (GVHD). Reduced intensity conditioning (RIC) regimens have decreased transplant related mortality but the incidence of acute GVHD, while delayed, remains unchanged. There are currently no in vivo allogeneic models of RIC HSCT, limiting studies into the mechanism behind RIC-associated GVHD. Methods. We developed two RIC HSCT models that result in delayed onset GVHD (major histocompatibility complex mismatched (UBI-GFP/BL6 [H-2(b)]-> BALB/c [H-2(d)]) and major histocompatibility complex matched, minor histocompatibility mismatched (UBI-GFP/BL6 [H-2(b)]-> BALB.B [H-2(b)])) enabling the effect of RIC on chimerism, dendritic cell (DC) chimerism, and GVHD to be investigated. Results. In contrast with myeloablative conditioning, we observed that RIC-associated delayed-onset GVHD is characterized by low production of tumor necrosis factor-a, maintenance of host DC, phenotypic DC activation, increased T-regulatory cell numbers, and a delayed emergence of activated donor DC. Furthermore, changes to the peritransplant milieu in the recipient after RIC lead to the altered activation of DC and the induction of T-regulatory responses. Reduced intensity conditioning recipients suffer less early damage to GVHD target organs. However, as donor cells engraft, activated donor DC and rising levels of tumor necrosis factor-a are associated with a later onset of severe GVHD. Conclusions. Delineating the mechanisms underlying delayed onset GVHD in RIC HSCT recipients is vital to improve the prediction of disease onset and allow more targeted interventions for acute GVHD.
引用
收藏
页码:968 / 976
页数:9
相关论文
共 50 条
  • [1] Acute graft-versus-host disease following hematopoietic stem-cell transplantation
    Hu, Stephanie W.
    Cotliar, Jonathan
    [J]. DERMATOLOGIC THERAPY, 2011, 24 (04) : 411 - 423
  • [2] Inflammatory cytokines and acute graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation
    Mohty, M
    Blaise, D
    Faucher, C
    Vey, N
    Bouabdallah, R
    Stoppa, AM
    Viret, F
    Gravis, G
    Olive, D
    Gaugler, B
    [J]. BLOOD, 2005, 106 (13) : 4407 - 4411
  • [3] Improved Survival in Lymphoma Patients Receiving Sirolimus for Graft-Versus-Host Disease Prophylaxis After Allogeneic Hematopoietic Stem-Cell Transplantation With Reduced-Intensity Conditioning
    Armand, Philippe
    Gannamaneni, Supriya
    Kim, Haesook T.
    Cutler, Corey S.
    Ho, Vincent T.
    Koreth, John
    Alyea, Edwin P.
    LaCasce, Ann S.
    Jacobsen, Eric D.
    Fisher, David C.
    Brown, Jennifer R.
    Canellos, George P.
    Freedman, Arnold S.
    Soiffer, Robert J.
    Antin, Joseph H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (35) : 5767 - 5774
  • [4] Risk of graft-versus-host disease with rituximab-containing conditioning regimens in allogeneic hematopoietic stem cell transplant
    Marini, Bernard L.
    Markstrom, Denise
    Frame, David
    [J]. JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2017, 23 (04) : 255 - 263
  • [5] Gastrointestinal Biopsies for Evaluation of Acute Graft-Versus-Host Disease in Allogeneic Hematopoietic Stem Cell Transplant Patients
    Azad, Shweta
    Malhotra, Veena
    Kirtani, Pawan
    Choudhary, Dharma
    [J]. INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2019, 35 (01) : 83 - 88
  • [6] Effect of acute graft-versus-host disease on the outcome of second allogeneic hematopoietic stem cell transplant in children
    Schechter, Tal
    Avila, Laura
    Frangoul, Haydar
    Domm, Jennifer
    Dupuis, L. Lee
    Naithani, Rahul
    Zhao, XiuYan
    Pollock-BarZiv, Stacey
    Roifman, Chaim
    Gassas, Adam
    Doyle, John
    [J]. LEUKEMIA & LYMPHOMA, 2013, 54 (01) : 105 - 109
  • [7] Evaluation of Tacrolimus Levels and Risk of Acute Graft-Versus-Host Disease in Allogeneic Hematopoietic Stem Cell Transplant
    Huynh, David Anh Huy
    Freeman, Tracelyn
    Marshall, Vincent
    Markstrom, Denise
    Frame, David
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03)
  • [8] Gastrointestinal Biopsies for Evaluation of Acute Graft-Versus-Host Disease in Allogeneic Hematopoietic Stem Cell Transplant Patients
    Shweta Azad
    Veena Malhotra
    Pawan Kirtani
    Dharma Choudhary
    [J]. Indian Journal of Hematology and Blood Transfusion, 2019, 35 : 83 - 88
  • [9] Lower dose of antithymocyte globulin does not increase graft-versus-host disease in patients undergoing reduced-intensity conditioning allogeneic hematopoietic stem cell transplant
    Salem, Galena
    Ruppert, Amy S.
    Elder, Patrick
    Hofmeister, Craig C.
    Benson, Don M.
    Penza, Sam
    Andritsos, Leslie
    Klisovic, Rebecca
    Vasu, Sumithira
    Blum, William
    Devine, Steven M.
    Jaglowski, Samantha
    Efebera, Yvonne A.
    [J]. LEUKEMIA & LYMPHOMA, 2015, 56 (04) : 1058 - 1065
  • [10] A novel reduced intensity regimen for allogeneic hematopoietic stem cell transplantation associated with a reduced incidence of graft-versus-host disease
    Miller, KB
    Roberts, TF
    Chan, G
    Schenkein, DP
    Lawrence, D
    Sprague, K
    Gorgun, G
    Relias, V
    Grodman, H
    Mahajan, A
    Foss, F
    [J]. BONE MARROW TRANSPLANTATION, 2004, 33 (09) : 881 - 889